First, the group of women with RA was relatively small but carefully selected according to the Polish National Health Fund Therapeutic Programs that employ TNF-blockers (i.e., B.33: “Treatment of aggressive forms of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA)” (03.0000.333.02) or B.45: “Treatment of an aggressive form of rheumatoid arthritis (03.0000.345.02)”). This evidence concerns the gene TNF and rheumatoid arthritis.